Mining And Ores Tenders

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Substance Glatiramer Acetate (Exclusively Pen Dosage Form), Atc L03ax13 for the Period 07/01/2023 - 06/30/2025

Medicines with the Active Substance Combination Glecaprevir and Pibrentasvir (Atc: J05ap57)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Open House Original Discount Agreements 2023-16 - Bimatoprost/Timolol (Dosage Form: Eye Drops as Single-Dose Pipettes)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Rivaroxaban

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Leuprorelin (L02ae02, H01ca04) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Somatropin, Atc H01ac01 for the Period 07/01/2023 - 06/30/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Fusidic Acid (Exclusively Dosage Form Ointment), Atc D06ax01 for the Period 07/01/2023 - 06/30/2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Sapropterin, Atc A16ax07 for the Period 07/01/2023 - 06/30/2025